Literature DB >> 30535084

A Simple, Rapid and Non-Radiolabeled Immune Assay to Detect Anti-AChR Antibodies in Myasthenia Gravis.

Suresh Bokoliya1, Shripad Patil1, Madhu Nagappa2, Arun Taly2.   

Abstract

OBJECTIVE: To assess the practicality of dot-blot testing for rapid and sensitive detection of the antiacetylcholine receptor (anti-AChR) antibodies in myasthenia gravis (MG).
METHODS: In this case-control study, we tested serum specimens of 85 patients with MG, 85 healthy control individuals, and 85 patients without MG who have other autoimmune and neurological illnesses. All the serum specimens were tested for anti-AChR antibodies using 3 assays: in-house enzyme-linked immunosorbent assay (ELISA), the dot-blot assay, and commercial ELISA.
RESULTS: In-house ELISA, commercial ELISA, and dot-blot test results were positive for anti-AChR antibodies in 65 (76.5%) patients with MG. The results of all 3 tests were negative for anti-AChR antibodies in healthy controls and patients without MG. We observed perfect concordance (K = 1, P <.001) between all 3 tests. In-house ELISA correlated significantly (r = 0.873, P <.001) with commercial ELISA. In-house ELISA and the dot-blot test demonstrated similar diagnostic performance in detecting anti-AChR antibodies.
CONCLUSIONS: The dot-blot assay is a simple, nonradioactive immune assay for rapid detection of anti-AChR antibodies in MG. © American Society for Clinical Pathology, 2018. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  ELISA; acetylcholine receptors; antibodies; dot blot; myasthenia gravis

Mesh:

Substances:

Year:  2019        PMID: 30535084     DOI: 10.1093/labmed/lmy038

Source DB:  PubMed          Journal:  Lab Med        ISSN: 0007-5027


  2 in total

Review 1.  Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management.

Authors:  Konstantinos Lazaridis; Socrates J Tzartos
Journal:  Front Neurol       Date:  2020-11-30       Impact factor: 4.003

Review 2.  Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics.

Authors:  Konstantinos Lazaridis; Socrates J Tzartos
Journal:  Front Immunol       Date:  2020-02-14       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.